5 results on '"Radu, Caius G."'
Search Results
2. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.
- Author
-
Koya, Richard C., Mok, Stephen, Comin-Anduix, Begoña, Chodon, Thinle, Radu, Caius G., Nishimura, Michael I., Witte, Owen N., and Ribas, Antoni
- Subjects
T cell receptors ,CANCER treatment ,LYMPHOCYTES ,INTERLEUKIN-2 ,BIOLUMINESCENCE ,POSITRON emission tomography - Abstract
A key issue in advancing the use of adoptive cell transfer (ACT) of T cell receptor OCR) engineered lymphocytes for cancer therapy is demonstrating how TCR transgenic cells repopulate lymphopenic hosts and target tumors in an antigen-specific fashion. ACT of splenocytes from fully immunocompetent HLA-A2.1/K
b mice transduced with a chimeric murine/human TCR specific for tyrosinase, together with lymphodepletion conditioning. dendritic cell (DC)-based vaccination, and highdose interleukin-2 (IL-2). had profound antitumor activity against large established MHC-and antigen-matched tumors. Genetic labeling with bioluminescence imaging (BU) and positron emitting tomography (PET) reporter genes allowed visualization of the distribution and antigen-specific tumor homing of TCR transgenic T cells, with trafficking correlated with antitumor efficacy. After an initial brief stage of systemic distribution, TCR-redirected and genetically labeled T cells demonstrated an early pattern of specific distribution to antigenmatched tumors and locoregional lymph nodes, followed by a more promiscuous distribution 1 wk later with additional accumulation in antigen-mismatched tumors. This approach of TCR engineering and molecular imaging reporter gene labeling is directly translatable to humans and provides useful information on how to clinically develop this mode of therapy. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
3. Requirement for deoxycytidine kinase in T and B lymphocyte development.
- Author
-
Toy, Gerald, Austin, Wayne R., Hsiang-l Liao, Donghui Cheng, Singh, Arun, Campbell, Dean O., Ishikawa, Tomo-o, Lehmann, Lynn W., Satyamurthy, Nagichettiar, Phelps, Michael E., Herschman, Harvey R., Czernina, Johannes, Witte, Owen N., and Radu, Caius G.
- Subjects
IMMUNODEFICIENCY ,LYMPHOCYTES ,LABORATORY mice ,CYTOLOGICAL research ,NUCLEOSIDES - Abstract
Deoxycytidine kinase (dCK) is a rate-limiting enzyme in deoxyribonucleoside salvage, a metabolic pathway that recycles products of DNA degradation. dCK phosphorylates and therefore activates nucleoside analog prodrugs frequently used in cancer. autoimmunity. and viral infections. In contrast to its well established therapeutic relevance, the biological function of dCK remains enigmatic. Highest levels of dCK expression are found in thymus and bone marrow, indicating a possible role in lymphopoiesis. To test this hypothesis we generated and analyzed dCK knockout (KO) mice. dCK inactivation selectively and profoundly affected T and B cell development. A 90-fold decrease in thymic cellularity was observed in the dCK KO mice relative to wild-type littermates. Lymphocyte numbers in the dCK KO mice were 5- to 13-fold below normal values. The severe impact of dCK inactivation on lymphopoiesis was unexpected given that nucleoside salvage has been thought to play a limited, fine-tuning role in regulating deoxyribonucleotide triphosphate pools produced by the de novo pathway. The dCK KO phenotype challenges this view and indicates that, in contrast to the great majority of other somatic cells, normal lymphocyte development critically requires the deoxyribonucleoside salvage pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
4. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.
- Author
-
Prins, Robert M., Shu, Chengyi J., Radu, Caius G., Vo, Dan D., Khan-Farooqi, Haumith, Soto, Horacio, Meng-Yin Yang, Muh-Shi Lin, Shelly, Stephanie, Witte, Owen N., Ribas, Antoni, and Liau, Linda M.
- Subjects
T cells ,TUMORS ,TUMOR antigens ,LUCIFERASES ,INTERLEUKIN-2 ,LYMPH nodes ,LYMPHOCYTES - Abstract
It is commonly believed that T cells have difficulty reaching tumors located in the brain due to the presumed “immune privilege” of the central nervous system (CNS). Therefore, we studied the biodistribution and anti-tumor activity of adoptively transferred T cells specific for an endogenous tumor-associated antigen (TAA), gp100, expressed by tumors implanted in the brain. Mice with pre-established intracranial (i.c.) tumors underwent total body irradiation (TBI) to induce transient lymphopenia, followed by the adoptive transfer of gp100
25–33 -specific CD8+ T cells (Pmel-1). Pmel-1 cells were transduced to express the bioluminescent imaging (BLI) gene luciferase. Following adoptive transfer, recipient mice were vaccinated with hgp10025–33 peptide-pulsed dendritic cells (hgp10025–33 /DC) and systemic interleukin 2 (IL-2). This treatment regimen resulted in significant reduction in tumor size and extended survival. Imaging of T cell trafficking demonstrated early accumulation of transduced T cells in lymph nodes draining the hgp10025–33 /DC vaccination sites, the spleen and the cervical lymph nodes draining the CNS tumor. Subsequently, transduced T cells accumulated in the bone marrow and brain tumor. BLI could also detect significant differences in the expansion of gp100-specific CD8+ T cells in the treatment group compared with mice that did not receive either DC vaccination or IL-2. These differences in BLI correlated with the differences seen both in survival and tumor infiltrating lymphocytes (TIL). These studies demonstrate that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
5. Visualization of a primary anti-tumor immune response by positron emission tomography.
- Author
-
Shu, Chengyi J., Shuling Guo, Kim, Young J., Shelly, Stephanie M., Nijagal, Amar, Ray, Pritha, Gambhir, Sanjiv S., Radu, Caius G., and Witte, Owen N.
- Subjects
POSITRON emission tomography ,IMMUNE response ,MEDICAL imaging systems ,BONE marrow ,IMMUNE system ,CELL proliferation ,LEUCOCYTES - Abstract
Current methodologies that monitor immune responses rely on invasive techniques that sample tissues at a given point in time. New technologies are needed to elucidate the temporal patterns of immune responses and the spatial distribution of immune cells on a whole-body scale. We describe a noninvasive, quantitative, and tomographic approach to visualize a primary anti-tumor immune response by using positron emission tomography (PET). Bone marrow chimeric mice were generated by engraftment of hematopoietic stem and progenitor cells transduced with a trifusion reporter gene encoding synthetic Renilla luciferase (hRluc), EGFP, and Herpes virus thymidine kinase (sr39TK). Mice were challenged with the Moloney murine sarcoma and leukemia virus complex (M-MSV/M-MuLV), and the induced immune response was monitored by using PET. Hematopoietic cells were visualized by using 9-[4-[
18 F]fluoro-3-(hydroxymethyl)butyl]guanine ([18 F]FHBG), a radioactive substrate specific for the sr39TK PET reporter protein. Immune cell localization and expansion were seen at the tumor and draining lymph nodes (DLNs). 2-[18 F]fluoro-2-deoxy-D-glucose ([18 F]FDG), which is sequestered in metabolically active cells, was used to follow tumor growth and regression. Elevated glucose metabolism was also seen in activated lymphocytes in the DLNs by using the [18 F]FDG probe. When M-MSV/M-MuLV-challenged mice were treated with the immunosuppressive drug dexamethasone, activation and expansion of immune cell populations in the DLNs could no longer be detected with PET imaging. The method we describe can be used to kinetically measure the induction and therapeutic modulations of cell-mediated immune responses. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.